Evaluation of serum amyloid a as a biomarker for gastric cancer

De-Chuan Chan, Cheng-Jueng Chen, Heng-Cheng Chu, Wei-Kuo Chang, Jyh-Cherng Yu, Yu-Ju Chen, Li-Li Wen, Su-Ching Huang, Chih-Hung Ku, Yao-Chi Liu, Jenn-Han Chen

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Background: Serum amyloid A (SAA) is a useful biomarker for gastric cancer in an animal model. We investigated the potential of SAA as a biomarker for gastric cancer in humans. Methods: Serum levels of SAA from 96 gastric cancer patients were measured before and after curative gastrectomy; 32 patients with gastric ulcers and 52 healthy subjects were the control groups. The immunohistochemical study was performed to evaluate the protein expression over gastric cancer tissue slides. Results: The mean SAA concentration was higher in gastric cancer patients (88.54 ± 50.44 mg/l) than in healthy subjects (3.36 ± 2.29 mg/l) and gastric ulcer patients (10.48 ± 8.97 mg/l) (P <.05). The SAA concentration was associated with tumor stage (P = .0244) and location (P = .0016) but not with Lauren's histological type (P = .839). In the multivariate analysis, SAA level was correlated with tumor location (P <.0001) and lymph node status (P <.05). During follow-up, the mean SAA concentration increased significantly in 24 patients with tumor recurrence (P <.05) but did not change in 77 patients without recurrence. In the survival analysis, patients with SAA levels > 97 mg/l had a nearly fourfold increase in risk of death. Immunoreactivity was most prominent in blood vessel regions but not within cancer cells. Conclusions: These data not only demonstrated SAA was useful in predicting survival of patients with gastric cancer, but they also showed that SAA was a valuable tool for postoperative follow-up. © 2006 Society of Surgical Oncology.
Original languageEnglish
Pages (from-to)84-93
Number of pages10
JournalAnnals of Surgical Oncology
Volume14
Issue number1
DOIs
Publication statusPublished - 2007
Externally publishedYes

    Fingerprint

Keywords

  • Mass spectrometry (MS)
  • Serum amyloid A (SAA) protein
  • Serum marker
  • Stomach neoplasm
  • biological marker
  • serum amyloid A
  • article
  • blood vessel
  • cancer cell
  • cancer patient
  • cancer survival
  • concentration response
  • controlled study
  • correlation analysis
  • disease marker
  • evaluation
  • follow up
  • gastrectomy
  • human
  • human tissue
  • immunohistochemistry
  • immunoreactivity
  • lymph node
  • major clinical study
  • measurement
  • mortality
  • multivariate analysis
  • protein expression
  • stomach cancer
  • stomach ulcer
  • tissue section
  • tumor recurrence
  • Adenocarcinoma
  • Aged
  • Female
  • Gastrectomy
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Serum Amyloid A Protein
  • Stomach Neoplasms
  • Stomach Ulcer
  • Survival Analysis
  • Tumor Markers, Biological

Cite this

Chan, D-C., Chen, C-J., Chu, H-C., Chang, W-K., Yu, J-C., Chen, Y-J., Wen, L-L., Huang, S-C., Ku, C-H., Liu, Y-C., & Chen, J-H. (2007). Evaluation of serum amyloid a as a biomarker for gastric cancer. Annals of Surgical Oncology, 14(1), 84-93. https://doi.org/10.1245/s10434-006-9091-z